InternationalUSRemember you can easily switch between MIP US and MIP International at any time

AbbVie v Amgen: Is the “patent dance” fair for both sides?

Natalie Rahhal, New York

Abbvie suing Amgen over its efforts to launch a Humira biosimilar is the first instance of parties not agreeing on which patents to be litigated under the BPCIA. The case poses the question of whether the patent dance strikes the right balance between parties

Abbvie logoAbbVie filed for an injunction against Amgen in the District of Delaware on August 4, claiming that Amgen’s efforts to have a biosimilar version of AbbVie’s widely-used Humira drug infringe its patents. 

The suit is the first...

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog

null null null



May / June 2019

From trademarks to trade secrets: in-house tips on brand protection in China

Despite the well-known struggles in protecting trademarks and trade secrets in China, there are some tried-and-tested strategies to employ, as Karry Lai and Ellie Mertens hear from in-house counsel at a range of domestic and international companies

Most read articles